cisplatin + carboplatin + paclitaxel (Azienda Ospedaliero-Universitaria Policlinico Umberto I)

The combination of cisplatin, carboplatin, and paclitaxel refers to a platinum-taxane chemotherapy regimen utilized as neoadjuvant chemotherapy (NACT) for the treatment of locally advanced cervical cancer (LACC). In the clinical context of studies conducted at Azienda Policlinico Umberto I, this regimen typically involves the administration of a platinum agent (either cisplatin or carboplatin) in combination with paclitaxel prior to radical surgery. The platinum agents, cisplatin and carboplatin, function by forming intra-strand and inter-strand DNA cross-links, which interfere with DNA replication and transcription, ultimately triggering apoptosis. Paclitaxel, a taxane, acts as a microtubule-stabilizing agent by binding to the beta-subunit of tubulin, which inhibits microtubule depolymerization and arrests the cell cycle in the G2/M phase. This combined approach aims to reduce primary tumor volume and address lymph node involvement (stages IIIC1 and IIIC2) to improve surgical feasibility and long-term survival outcomes.

Other names

Platinum-taxane neoadjuvant chemotherapyNACT regimen